Sun Pharma - Addressing the Oral IL-23 Antagonist Challenge to Ilumya
Emkay Global Financial's research report on Sun Pharma J&J, in a recent investor interaction, had stated that its oral IL-23 receptor antagonist...
226 Views
Pharmaceuticals: IPM: growth recovers to 11.7% in Oct-25
In chronic space, cardiac continues to drive IPM growth in Oct-25 at 17% YoY (+11% in Q2FY26), anti-diabetic at 15% (+9% in Q2FY26), led by...
128 Views
Pharmaceuticals: IPM: grows 6.1% in Sep’25 and 7.2% in Q2FY26
The strong growth in cardiac, respiratory, and oncology was offset by muted growth in anti-infective, gastro, VMN, and pain. For Q2FY26, IPM grew...
218 Views
Pharma and Healthcare (Q2FY26E Results Preview): Q2FY26: Steady sales growth, margin to remain flat
The India Pharma and Healthcare sector is expected to see steady revenue growth but EBITDA margins to remain flatWe project sales/EBITDA growth of...
238 Views
Pharmaceuticals: IPM: steady 8% growth in Aug-25
As per IQVIA, IPM saw 8.1% YoY growth in Aug-25 (7.1%% YoY in Jul-25, 9% YoY in Q1FY26, and 8% in FY25) with 0.8% YoY decline in units.
195 Views